Editor’s Choice
Academic Journal
Main Category: Diabetes
Also Included In: Stem Cell Research; Transplants / Organ Donations
Article Date: 01 Jul 2013 – 0:00 PDT
If you write about specific medications or operations, please do not name health care professionals by name.
Type 2 diabetes patients who receive self-donated (autologous) bone marrow stem cells require less insulin, a new study revealed.
However, a “repeated emphasis on life style modification” was thought to be playing a factor in this effect.
A recent study showed that going for short walks after meals may reduce the risk of type 2 diabetes in older people by helping to reduce the risky spikes in blood sugar that occur after filling the stomach with food.
“There is growing interest in the scientific community for cellular therapies that use bone marrow-derived cells for the treatment of type 2 diabetes mellitus and its complications. But the potential of stem cell therapy for this disease is yet to be fully explored.”
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Study corresponding author Anil Bhansali, PhD, professor and head of the Endocrinology Department at the Post Graduate Institute of Medical Education in Chandrigarh, India, said:
Please note: If no author information is provided, the source is cited instead.
Glynn, Sarah. “Type 2 Diabetes Patients Benefit From Bone Marrow Stem Cell Transplants.” Medical News Today. MediLexicon, Intl., 1 Jul. 2013. Web.
3 Jul. 2013. <http://www.medicalnewstoday.com/articles/262707.php>
A notably smaller decrease in the need for insulin was also observed in the control group.
The research, published in Cell Transplantation, was carried out in India and looked at the safety and efficacy of autologous transplanted bone marrow stem cells in patients with type 2 diabetes (TD2M).
The study included a homogenous patient population with T2DM who displayed good glycemic control and the existence of a comparable control group that did not receive cell transplants, Dr. Bhansali pointed out.
The researchers said:
Good glycemic control appeared as a critical factor in the transplantation group and in the non-transplanted control group.
“The efficacy and safety of stem cell therapy needs to be established in a greater number of patients and with a longer duration follow-up. The data available so far from animal and human studies is encouraging, however, it has enormous limitations.”
“Autologous bone marrow-derived stem cell therapy in patients with T2DM results in significant decrease in insulin dose requirement,” the authors concluded.
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
“By experimenting with bone marrow-derived stem cells, the researchers sought to exploit the rich source of stem cells in bone marrow,” the researchers said.
The experts wanted to examine the efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with T2DM and who also had good glycemic control.
The experts suggested finding out which type of stem cells (bone marrow, hematopoietic, or placenta-derived) might be best for the treatment of T2DM.
Although there is an increasing interest in using stem cell transplantation to treat people with this condition, there has been little research observing the benefit of bone marrow-derived stem cells.
APA
Contact Our News Editors
